<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="id">3599</item><item key="factors"><item><item key="GSM518494 1"/></item><item><item key="GSM518495 1"/></item><item><item key="GSM518496 1"/></item><item><item key="GSM518497 1"/></item><item><item key="GSM542393 1"/></item><item><item key="GSM542394 1"/></item><item><item key="GSM542395 1"/></item><item><item key="GSM542396 1"/></item><item><item key="GSM542397 1"/></item><item><item key="GSM542398 1"/></item><item><item key="GSM542399 1"/></item><item><item key="GSM542400 1"/></item><item><item key="GSM542401 1"/></item><item><item key="GSM542402 1"/></item><item><item key="GSM542403 1"/></item><item><item key="GSM542404 1"/></item><item><item key="GSM542405 1"/></item><item><item key="GSM542406 1"/></item><item><item key="GSM542407 1"/></item><item><item key="GSM542408 1"/></item></item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">The NF-&#954;B pathway is a critical regulator of the immune system and has been implicated in cellular transformation and tumorigenesis. NF-...</item><item key="pubmed_id">20832754</item><item key="geo_gse_id">E-GEOD-20667</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">0</item><item key="sample_count">20</item><item key="tags"><item>cell</item><item>disease</item><item>immune system</item><item>leukemia</item><item>line</item><item>notch</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">the-notchhes1-pathway-sustains-nf-b-activation-thr</item><item key="geo_id_plat">E-GEOD-20667_A-AFFY-44</item><item key="name">The Notch/Hes1 pathway sustains NF-&#954;B activation through CYLD repression in T cell leukemia</item><item key="created">Sep.15, 2014</item><item key="summary">The NF-&#954;B pathway is a critical regulator of the immune system and has been implicated in cellular transformation and tumorigenesis. NF-&#954;B response is regulated by the activation state of the I&#954;B kinase (IKK) complex and triggered by a wide spectrum of stimuli. We previously reported that NF-&#954;B is downstream of Notch1 in T cell acute lymphoblastic leukaemia (T-ALL), however both the mechanisms involving Notch1-induced NF-&#954;B activation and the potential importance of NF-&#954;B in the maintenance of the disease are unknown. Here we visualize Notch-induced NF-&#954;B activation using both human T-ALL cell lines and animal models of this type of leukemia. We show that it is not Notch1 itself but Hes1, a canonical Notch target, the responsible for sustaining IKK activation in T-ALL. Hes1 exerts its effects by a direct transcriptional repression of the deubiquitinating enzyme CYLD, a well-characterized IKK inhibitor. Consistently, CYLD expression is significantly reduced in primary T-ALL leukemias. Finally, we demonstrate that IKK complex inhibition is a promising option for the targeted therapy of T-ALL as suppression of IKK function affected both the survival of human T-ALL cells in vitro and the maintenance of the disease in vivo. Transcriptional consequences of NF-kB inactivation in human T-ALL1 cell line Twenty samples were analyzed: human T-ALL, CEM, KOPT-K, DND41, HPB-ALL cells lines have been treated at 100uM for 16 hours with control peptide or IKK&#947; Nemo binding domain (NBD) inhibitory peptide, that specifically block the canonical NF-&#954;B activity by disrupting the interaction of IKK&#947; to IKK&#946; and IKK&#945;</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-20667</item><item key="species">human</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-20667/samples/</item></data></biogps>
